<DOC>
	<DOC>NCT02307643</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus</brief_summary>
	<brief_title>Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of SLE based on the American College of Rheumatology (ACR) criteria Presence of at least one of the following items: positive anti dsDNA antibodies, low complement levels, and so on. Stable doses of corticosteroids Severe active lupus nephritis, neuropsychiatric SLE</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
</DOC>